Department of Cardiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77025, USA.
Division of Cardiovascular Medicine, University of Texas Health Science Center, Houston, TX, USA.
Curr Cardiol Rep. 2020 Oct 10;22(12):171. doi: 10.1007/s11886-020-01421-y.
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread with rising new cases and deaths. Patients with cancer represent a uniquely vulnerable population not only with higher susceptibility to COVID-19 but also at increased risk for its complications. This review focuses on the implications of COVID-19 in the cardiovascular health of patients with cancer.
Patients more susceptible to COVID-19 with increased severity of disease include those with cancer and cardiovascular comorbidities. In addition, the cardiovascular complications of COVID-19 including acute myocardial injury, thromboembolism, cardiomyopathy, myocarditis, and pericardial disease overlap with many of those encountered during cancer treatment. Despite the absence of large studies of patients with both cancer and cardiovascular disease, the incidence of cardiovascular complications in cancer patients with COVID-19 is expected to be high. This has implications for cardiac monitoring, chemotherapy administration, and the diagnosis and treatment of cardiovascular disease during COVID-19.
由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）大流行仍在继续蔓延，新发病例和死亡人数不断上升。癌症患者不仅更容易感染 COVID-19，而且其并发症的风险也更高，他们是一个独特的脆弱群体。本综述重点关注 COVID-19 对癌症患者心血管健康的影响。
COVID-19 易感性更高且疾病严重程度增加的患者包括癌症和心血管合并症患者。此外，COVID-19 的心血管并发症，包括急性心肌损伤、血栓栓塞、心肌病、心肌炎和心包疾病，与癌症治疗期间遇到的许多并发症重叠。尽管缺乏同时患有癌症和心血管疾病的患者的大型研究，但 COVID-19 癌症患者的心血管并发症发生率预计会很高。这对 COVID-19 期间的心脏监测、化疗管理以及心血管疾病的诊断和治疗都有影响。
